Several studies with novel agents, such as BLU-285, crenolanib in patient harboring highly resistant mutation of PDGFRA D842V (78, 79), dabrafenib in BRAF-mutated GIST (80), are being tested with some early signs of benefit. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.